Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

Benzinga · 3d ago
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.